KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Travere Therapeutics (TVTX) Other Gross PP&E Adjustments (2016 - 2025)

Travere Therapeutics' Other Gross PP&E Adjustments history spans 11 years, with the latest figure at -$10.4 million for Q4 2025.

  • For Q4 2025, Other Gross PP&E Adjustments rose 34.36% year-over-year to -$10.4 million; the TTM value through Dec 2025 reached -$10.4 million, up 34.36%, while the annual FY2025 figure was -$10.4 million, 34.36% up from the prior year.
  • Other Gross PP&E Adjustments reached -$10.4 million in Q4 2025 per TVTX's latest filing, up from -$11.5 million in the prior quarter.
  • In the past five years, Other Gross PP&E Adjustments ranged from a high of -$10.4 million in Q4 2025 to a low of -$29.7 million in Q4 2022.
  • Average Other Gross PP&E Adjustments over 5 years is -$19.6 million, with a median of -$19.9 million recorded in 2023.
  • Peak YoY movement for Other Gross PP&E Adjustments: surged 37.3% in 2021, then dropped 9.79% in 2022.
  • A 5-year view of Other Gross PP&E Adjustments shows it stood at -$27.0 million in 2021, then decreased by 9.79% to -$29.7 million in 2022, then increased by 16.66% to -$24.7 million in 2023, then skyrocketed by 35.81% to -$15.9 million in 2024, then soared by 34.36% to -$10.4 million in 2025.
  • Per Business Quant, the three most recent readings for TVTX's Other Gross PP&E Adjustments are -$10.4 million (Q4 2025), -$11.5 million (Q3 2025), and -$12.3 million (Q2 2025).